Atlas Trials

Relapsed Acute Myeloid Leukemia

18 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsed Acute Myeloid Leukemia

RecordFirmDate
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS (NCT04893915)Washington University School of Medicine2022-06-30
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (NCT04797767)University of Washington2022-02-04
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies (NCT04891757)Foghorn Therapeutics Inc.2021-06-14
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) (NCT04582864)Washington University School of Medicine2021-05-20
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML (NCT05456048)Nanfang Hospital, Southern Medical University2018-12-03
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia (NCT02996474)National Heart, Lung, and Blood Institute (NHLBI)2016-12-16
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (NCT02109627)C. Babis Andreadis2015-05-01
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01961765)Massachusetts General Hospital2013-11-01

Track Relapsed Acute Myeloid Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.